Clinical efficacy and safety of Lyprinol, a patented extract from New Zealand green-lipped mussel (Perna Canaliculus) in patients with osteoarthritis of the hip and knee: a multicenter 2-month clinical trial.

Abstract

OBJECTIVE:

To validate the clinical efficacy and safety of Lyprinol (a patented extract from Perna Canaliculus), a 5-LOX inhibitor in patients with osteoarthritis.

METHODS:

In this multicenter trial, 60 patients with symptomatic osteoarthritis of the knee and hip were included to receive Lyprinol at a dose of 2 capsules twice a day. After a 4- and 8-week treatment period, the following parameters were analyzed: visual analogue scale; Lequesne functional index; global assessment by patients; global assessment by physician; and adverse effects.

RESULTS:

Lyprinol treatment led to significant improvement of the signs and symptoms of osteoarthritis as determined by all efficacy measures. After a 4- and 8-week treatment period, 53% and 80% (respectively) of patients experienced significant pain relief, and improvement of joint function. There was no reported adverse effect during this clinical trial.

CONCLUSION:

Lyprinol was very effective and is a promising anti-inflammatory product that relieves the signs and symptoms of osteoarthritis, without adverse effect.

• Authors: Se Haeng Cho, Young Bok Jung, Sang Cheol Seong, Hyung Bin Park, Ki Yong Byun, Dong Chul Lee, Eun Kyoo Song, Jung Hwan Son
• Journal: European annals of allergy and clinical immunology (Eur Ann Allergy Clin Immunol) Vol. 35 Issue 6 Pg. 212-6 (Jun 2003) ISSN: 1764-1489 [Print] Italy
• PMID: 12872680 (Publication Type: Clinical Trial, Journal Article, Multicenter Study)

Chemical References

• Anti-Inflammatory Agents, Non-Steroidal
• Fatty Acids, Omega-3
• Leukotriene Antagonists
• Lipids
• Lipoxygenase Inhibitors
• Tissue Extracts
• lyprinol

Topics

• Aged
• Animals
• Anti-Inflammatory Agents, Non-Steroidal (adverse effects, therapeutic use)
• Bivalvia (chemistry)
• Fatty Acids, Omega-3 (adverse effects, therapeutic use)
• Female
• Humans
• Leukotriene Antagonists (adverse effects, therapeutic use)
• Lipids (adverse effects, therapeutic use)
• Lipoxygenase Inhibitors
• Male
• Middle Aged
• Osteoarthritis, Hip (drug therapy)
• Osteoarthritis, Knee (drug therapy)
• Safety
• Tissue Extracts (therapeutic use)
• Treatment Outcome